MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2022 International Congress

    May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

    A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

    Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • 2022 International Congress

    Apomorphine Hydrochloride Injection Treatment Initiations in the Presence and Absence of an Antiemetic in People with Parkinson Disease

    C. Happel, M. Grall, B. Lujan, A. Formella (Rockville, USA)

    Objective: To provide real-world experience regarding apomorphine treatment initiations with or without concomitant antiemetic prophylaxis. Background: Apomorphine hydrochloride (apo) injection, administered subcutaneously, is an “on-demand’…
  • 2022 International Congress

    Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

    M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

    Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…
  • 2022 International Congress

    Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.

    SW. Pedersen, L. Johannsen (Frederiksberg, Denmark)

    Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…
  • 2022 International Congress

    Efficacy of Apomorphine Sublingual Film Versus Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    F. Stocchi, O. Rascol, W. Poewe, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Rome, Italy)

    Objective: Evaluate efficacy and patient satisfaction associated with apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with…
  • 2022 International Congress

    Apomorphine Sublingual Film Versus Subcutaneous Apomorphine in the Treatment of OFF Episodes in Parkinson’s Disease: Results From an Assessment of Patient Satisfaction

    J. Schwarz, C. Carroll, G. Ebersbach, J. Kulisevsky, A. Tessitore, I. Zhang, A. Bowling, S. Wu, E. Pappert, A. Thach (Oberbayern, Germany)

    Objective: Evaluate treatment satisfaction with apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease (PD).…
  • 2022 International Congress

    Apomorphine Sublingual Film Titrated at Home in Patients With Parkinson’s Disease and OFF Episodes: Results From an Open-Label, Randomized, Crossover Study

    J. Kassubek, F. Stocchi, E. Balaguer, S. Isaacson, I. Zhang, A. Bowling, S. Wu, E. Pappert (Ulm, Germany)

    Objective: Evaluate the ability of patients with Parkinson’s disease (PD) and OFF episodes to achieve an effective and tolerable FULL ON dose of apomorphine sublingual…
  • 2022 International Congress

    Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    O. Rascol, W. Poewe, F. Stocchi, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Toulouse, France)

    Objective: Evaluate safety and tolerability of apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease…
  • 2022 International Congress

    Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

    Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley